NEW DELHI, Sept 18 - If the advanced clinical trials of COVID-19 vaccine succeed, then an effective vaccination is likely to be available by the end of first quarter of 2021, Minister of State for Health Ashwini Choubey informed Lok Sabha on Friday.
He was responding to a question about the time by which an effective COVID-19 vaccine is likely to be commercially launched.
The Minister further said that no advance purchase agreement with any vaccine manufacturers have been entered into.
Responding to another question, Choubey said that the Phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research (ICMR) and Cadila Healthcare Ltd and now their immunogenicity testing is in progress.
Their Phase II clinical trials are ongoing.
The Government of India has formed a National Expert Group on Vaccine Administration for COVID-19 chaired by Member (Health), Niti Aayog, which is creating a strategy on the procurement mechanisms for vaccine, including both indigenous and international manufacturing, along with guiding principles for prioritisation of population groups for vaccination, Choubey said.
The Expert Group has deliberated on broad parameters guiding the selection of COVID-19 vaccine candidates for the country and working in close coordination with Standing Technical Sub-Committee of National Technical Advisory Group on Immunization (NTAGI), he said in a written reply to Lok Sabha.
The Central Drugs Standard Control Organisation (CDSCO) has granted test license permission for manufacture of COVID-19 vaccine for preclinical test, examination and analysis to 7 manufacturers in India. These are Serum Institute of India in Pune, Cadila Healthcare Ltd., Ahmedabad, Bharat Biotech International Ltd in Hyderabad, Biological E Ltd., Hyderabad, Reliance Life Sciences Pvt Ltd in Mumbai, Aurbindo Pharma Limited in Hyderabad and Gennova Biopharmaceuticals Limited, Pune. � PTI
NEW DELHI, Sept 18 - If the advanced clinical trials of COVID-19 vaccine succeed, then an effective vaccination is likely to be available by the end of first quarter of 2021, Minister of State for Health Ashwini Choubey informed Lok Sabha on Friday.
He was responding to a question about the time by which an effective COVID-19 vaccine is likely to be commercially launched.
The Minister further said that no advance purchase agreement with any vaccine manufacturers have been entered into.
Responding to another question, Choubey said that the Phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research (ICMR) and Cadila Healthcare Ltd and now their immunogenicity testing is in progress.
Their Phase II clinical trials are ongoing.
The Government of India has formed a National Expert Group on Vaccine Administration for COVID-19 chaired by Member (Health), Niti Aayog, which is creating a strategy on the procurement mechanisms for vaccine, including both indigenous and international manufacturing, along with guiding principles for prioritisation of population groups for vaccination, Choubey said.
The Expert Group has deliberated on broad parameters guiding the selection of COVID-19 vaccine candidates for the country and working in close coordination with Standing Technical Sub-Committee of National Technical Advisory Group on Immunization (NTAGI), he said in a written reply to Lok Sabha.
The Central Drugs Standard Control Organisation (CDSCO) has granted test license permission for manufacture of COVID-19 vaccine for preclinical test, examination and analysis to 7 manufacturers in India. These are Serum Institute of India in Pune, Cadila Healthcare Ltd., Ahmedabad, Bharat Biotech International Ltd in Hyderabad, Biological E Ltd., Hyderabad, Reliance Life Sciences Pvt Ltd in Mumbai, Aurbindo Pharma Limited in Hyderabad and Gennova Biopharmaceuticals Limited, Pune. � PTI
